Global Academic Journal of Pharmacy and Drug Research

Available online at https://www.gajrc.com
DOI: https://doi.org/10.36348/gajpdr.2025.v07i01.001

OPEN ACCESS

ISSN (P): 2706-9044
ISSN (O): 2707-255X

Review Article

A Brief Insights on Gauchers Disease

Samudrala Pradeep[1*], Pallikonda Sharanya[2]
[1]Student, Department of Pharmacy Practice, Vaagdevi Institute of Pharmaceutical Sciences, Bollikunta, Warangal, Telangana, 506005, India

***Corresponding Author**
Samudrala Pradeep
Student, Department of Pharmacy Practice, Vaagdevi Institute of Pharmaceutical Sciences, Bollikunta, Warangal, Telangana, 506005, India

Article History
Received: 27.12.2024
Accepted: 01.02.2025
Published: 07.02.2025

Abstract: Gaucher's disease is not very common. Types II and III, which involve less than 1 in 100,000 people, are extremely uncommon and have various degrees of neurologic system involvement. The most present lysosomal storage disorder is type I Gaucher's disease, which affects mostly adults. Although Type I illness is still rare affecting roughly 1 in 30 to 40000 people, experience in the UK indicated that over 90 to 95% of patients have it. Cellular malfunction and behavioral issues emerge from the lysosomal dysfunction that follows. In sphingolipidoses, Gaucher disease is the most prevalent. In 1882, Philippe Gaucher discovered a patient that had significant splenomegaly who lacked leukemia. GBA1 gene mutations on the chromosome cause GD, a rare, autosomal, recessive inherited condition. The major decrease in GCase activity occurs by mutations in the GBA1 gene. This deficiency's effects are generally ascribed to the deposits of the GCase substrate, GlcCer, in macrophages, which leads them to change into Gaucher cells, as per the most recent studies, Gaucher cells are a new M2 subpopulation that arises from another differentiation mechanism and is not just the consequence of macrophage cell transformation. Other than of getting fully polarized and receiving a specific type of cell such as M1 or M2, macrophages can exhibit a variety of functional stages of polarization. Ferritin binds iron and stops toxicity to cell their supporters. In GD, hepcidin earnings, which prohibits intestinal absorption of iron, is up, while ferritin levels in Gaucher cells are enhanced. Certain cytokines (IL-6 and IL-1β) in Gaucher cells can boost the transcription of the hepcidin gene. Establishing poor G Case activity in total leukocytes, mononuclear cells, or cultured fibroblasts must be done to prove the diagnosis of GD. In many instances, the other enzyme activity is 10% to 15% of the normal value.

Keywords: β-glucosidase, Gaucher disease, hydrolyzes glucosylceramide (GlcCer), Lysosomal storage diseases, pseudo-Gaucher, sphingosine-1-phosphate.

INTRODUCTION

A group of multiple inherited illnesses termed lysosomal storage diseases (LSDs) are brought on by mutations in genes that either encodes the function of the lysosomal enzymes necessary for the degradation of a number of complex macromolecules or, on occasions, the function of particular transporters required for the export of broken-down molecules from the lysosomes. Cellular malfunction and behavioral issues emerge from the lysosomal dysfunction that follows. The ability of the metabolites, which constitute vital parts of cell membranes and regulators in many signaling pathways, to be broken back for enzymes is impaired in one class of LSDs, associated with sphingolipidoses [1].

DEFINITION

In sphingolipidoses, Gaucher disease is the most prevalent. In 1882, Philippe Gaucher discovered a patient that had significant splenomegaly who lacked leukemia. GBA1 gene mutations on the chromosome cause GD, a rare, autosomal, recessive inherited condition. The lysosomal enzyme glucocerebrosidase commonly referred to as glucosylceramidase or acid β-glucosidase, hydrolyzes glucosylceramide (GlcCer) into ceramide and glucose as the result of this, and its activity decreases markedly. The GBA1 gene has been shown to carry around 300 GBA mutations [2].

Because the phenotypic varies, three clinical forms have been identified: types 2 and 3 are defined by neurological impairment, whereas type 1 is the most noticeable and broadly does not cause any neurological attack. Such variations are not absolute, though, and it is becoming recognized more widely that neuropathic GD is a continuum of problems, from the middle end of extrapyramidal syndrome in type 1 to severe end of hydrops fetalis in type 2 [3].

CAUSES

A lack of glucocerebrosidase, an enzyme necessary for the lysosomal breakdown of lipids containing covalently bonded sugars, results in Gaucher's disease, an autosomal recessive disorder. The highly insoluble glucocerebroside (glucosylceramide) builds up when it is absent [20]. Rarely, a deficiency of a saposin, a heat-stable cofactor necessary for the regular catalytic function of glucocerebrosidase, may occur instead of a deficiency of the enzyme itself, which occurs in the great majority of instances.The glucocerebrosidase gene is found in the q21.36 region of chromosome 1. Clinical findings and variations in the kinetic characteristics of the remaining enzyme in various people with Gaucher's disease led to the conclusion that a variety of distinct mutations cause the condition [21].

EPIDEMIOLOGY

Gaucher's disease is not very common. Types II and III, which involve less than 1 in 100,000 people, are extremely uncommon and have various degrees of neurologic system involvement. The most present lysosomal storage disorder is type I Gaucher's disease, which affects mostly adults. Although Type I illness is still rare affecting roughly one in 30 to forty thousand people, experience in the UK indicated that over 90 to 95% of patients have it. The incidence of the disorder is much higher among Ashkenazi Jews, with a prevalence of approximately 1 in 1000 and an estimated carrier frequency of 1:14, according to epidemiological study carried out in the USA and Israel [4].

GENETIC COUNSELING:

In order to identify individuals who are heterozygous for Gaucher's disease, techniques for testing the relevant β-glucosidase in peripheral blood leukocytes were developed. The results for heterozygotes and normal individuals still significantly overlap, despite numerous attempts to increase the selective strength of enzyme assays. With DNA analysis, known mutations can be found with far greater accuracy. The identification of about 95% of the alleles in the Jewish population and 75% of those in the non-Jewish population has been made possible by the recent discovery of a second common mutation. It is not too difficult for couples who have already had a child with Gaucher's disease to receive genetic counselling [18].

A chorionic-villus sample's fetal DNA analysis should be trustworthy if both parental mutations have been detected at the DNA level. The fetus can be diagnosed with the condition via enzymatic testing on cultured amniotic fluid cells if one or both of the parental mutations are unknown. All afflicted offspring will have the same disease genotype because both parents are often heterozygous. Even though there is considerable variation across siblings, a comparatively high degree of concordance is typically seen, allowing the affected child's clinical course to be used to forecast the disease phenotype quite accurately. When a couple seeks information because one of its members has Gaucher’s disease.

Supplying extremely accurate information regarding the two potential parents' carrier states. Because of the powerful nature of DNA analysis, population-based screening, like that being done for Tay-Sachs disease, is now feasible. A kid born to a couple who neither parent carries one of the frequent mutations is less likely to have Gaucher's disease than one in 500,000. However, if the enzyme activity of the leukocytes of the possible parent with no detectable mutation is normal, the risk is far reduced. If one has a mutation for Gaucher's disease and the other does not, the risk is approximately 1 in 1000. Because the 1226G mutation is so common [19].

PATHOPHYSIOLOGY

Accumulation of Glucosylceramidase: The major decrease in GCase activity occurs by mutations in the GBA1 gene. This deficiency's effects are generally ascribed to the deposits of the GCase substrate, GlcCer, in macrophages, which leads them to change into Gaucher cells. When Gaucher cells are shown under a light the microscope, they usually appear growing, with eccentric nuclei and condensed cytoplasm and chromatin that like "crumpled tissue paper”. The discovery of GlcCer aggregates in distinctive twisted, fibrillar designs that are visible

through electron microscopy is linked to these things. Though they also infiltrate other organs, gaucher cells are thought to be the main reason of the disease's symptoms. They mostly infiltrate the liver, spleen, and bone marrow [5].

Subpopulation of Gaucher Cells, A Particular Cell Type as per the most recent studies, Gaucher cells are a new M2 subpopulation that arises from another differentiation mechanism and is not just the consequence of macrophage cell transformation. Other than of getting fully polarized and receiving a specific type of cell such as M1 or M2, macrophages can exhibit a variety of functional stages of polarization. These different habits are contingent upon the tissue and microenvironment in which the macrophages are located. The M2 subpopulation comprises macrophages that clear aberrant hematopoietic cells or phagocytose erythroblast nuclei, and has been established as cells creating anti-inflammatory, immunomodulatory, and tissue healing functions. Given the simultaneous activation of inflammatory molecules in the plasma cytokine profile and the specific characteristics of monocytes circulating in the blood, the in vivo that seem even more complex [6].

Variations in Iron Metabolism

Ferritin binds iron and stops toxicity to cell their supporters. In GD, hepcidin earnings, which prohibits intestinal absorption of iron, is up, while ferritin levels in Gaucher cells are enhanced. Certain cytokines (IL-6 and IL-1β) in Gaucher cells can boost the transcription of the hepcidin gene; the macrophages that are activated in this manner can also cause iron retention using an autocrine mechanism [70] while lowering glycosylation capabilities, which decrease the content of glycosylated ferritin [7].

Metabolic Impacts in Addition Glucosylceramide Formation in Gaucher Cells

In a mouse model, Mistry *et al*., reported a new metabolic route as a result of the increase of GlcCer. Another pathway uses GlcCer as its substrate, where a ceramidase transform it to glucosylsphingosine, which diffuses into fluids through its dipped hydrophobicity. When there is GCase deficiency, this pathway is liked most. A second GCase that is active at a neutral pH (GBA2 gene) disregards down glucosylsphingosine in the cytoplasm into sphingosine and further sphingosine-1-phosphate (S1P) [8].

DIAGNOSIS OF GAUCHER DISEASE

GD is usually identified several years after those first clinical and laboratory evidence appear. When rare diseases have a progressive outbreak of symptoms, this is a frequent issue.

Activity of G case

Establishing poor G Case activity in total leukocytes, mononuclear cells, or cultured fibroblasts must be done to prove the diagnosis of GD. In many instances, the other enzyme activity is 10% to 15% of the normal value.

Although dried blood spots may also be used for the enzymatic assay, the prior mentioned procedure should be performed to confirm any possible problems. Although it has not been verified by another organization, the flow cytometry test of blood monocytes is a more accurate technique. One should get checked for the extremely uncommon saposin C deficiency [9].

The Aspiration of Bone Marrow:

Even bone marrow aspiration does not have to confirm a diagnosis of GD, it can be helpful when Gaucher cells are detected and may be carried out on those who do not yet have a diagnosis if isolated thrombocytopenia and/or splenomegaly are discovered. But with GD, bone marrow aspiration may not be done more often. In certain occasions, when there are only a few cells available, cytology may not be able to make a diagnosis. Additionally, it could be extremely difficult to establish separate Gaucher cells from the so-called "pseudo-Gaucher" cells shown in some viral diseases or blood disorders, such myeloma with histiocytic plaque of immunoglobulin crystals [10].

Mutations in GBA1

The GCase-encoding gene (GBA1) includes 11 exons and exists on chromosome 1's long arm (1q21). Recombination events between GBAP and GBA1 are brought on by the presence of a highly homologous pseudogene (GBAP) at the same locus. The GBA1 gene has more than 400 recognized variants, nonetheless some are more commonly observed than somebody else, for example RecNciI, c.1226A>G (N370S), c.1448T>C (L444P), c.84dup, and c.115+1G>A (IVS2+1G>A) [11].

Prenatal Evaluations

Chorionic villus sampling (taken at 10–12 weeks of amenorrhea) or amniotic fluid cells can be used for genetic analysis to accomplish prenatal diagnosis of GD, but only if the index case genotype has already been identified. Another process is to determine the activity of glucocerebrosidase on cultured amniotic cells or fresh chorionic villi [12].

LABORATORY TECHNIQUES

Both patients and control subjects endured serum examinations for calcium (Ca), phosphorus (P), bone alkaline phosphatase (ALP) isoenzyme, carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen

(ICTP), osteocalcin, and intact parathyroid hormone (PTH) following an overnight fast at baseline and during the follow-up period. The second morning void (2-an hour fasting) was implemented to measure the urinary excretion of phosphorous, calcium, hydroxyproline, and free deoxypyridinoline, unifying on creatinine excretion. An automatic Cobas Integra Roche detector was used to find the total ALP. PICP and ICTP had been detected by radioimmunoassay (Orion Diagnostica); the bone ALP isoenzyme was obtained together with other ALP isoenzymes using electrophoresis in agarose gel (HELENA, Beaumont, Tx, USA). as osteocalcin reference values were changed during patient recruitment, this marker was omitted in the analysis. The radioimmunometric assay (Diagnostic Systems Laboratories, Webster, TX, USA) was used to determine intact PTH. Using a fluorimetric detector and high-performance liquid chromatography (HPLC), hydroxyproline was evaluated. Using a monoclonal antibody method and competitive immunoassay, free deoxypyridinoline was identified (Pyrilinks-D, Metra Bio system, DPC, CA, USA). Densitometric and laboratory analyses occurred at baseline, six and 12 months after that, and next regularly for 4.4 to 6 years (mean 4.5 years) [13].

TREATMENT

General Specific Interventions

Regular monitoring is critical for all GD patients, although not all situations call for the use of a particular drug. In the majority of circumstances, treatment must be given across the rest of one's life after it has begun. GD is now receiving two distinct tactics: substrate reduction therapy (SRT) and enzyme replacement therapy (ERT). The objective is to treat patients prior to the development of difficulties, such as large fibrous splenomegaly, AVN, secondary osteoarthritis, spinal compression and other fractures, hepatic fibrosis, and lung fibrosis, whose aftereffects are incapacitating or cannot be alleviated by extra care [14].

GENE THERAPY

With the goal to add the GBA1 gene into hematopoietic cells and subsequently inject the corrected cells into patients, a preliminary gene transfer approach was employed on GD3 patients (191). The GCase levels were too low to have any clinical impact. He which led to poor results. Although lentiviral vector gene transfer systems have shown hopeful results in mice models of GD, this therapy is still in its early stages of exploration [15].



Figure 1: A vertebral fracture in a Gaucher disease patient [16]

CONCLUSION

Gaucher disease is the most prevailing of the lysosomal storage diseases, although it is still unheard of, and the majority of cases have a progressive onset phenotype, making up for the delayed diagnosis. To prevent potentially dangerous splenectomy, GD must be included in the diagnostic decision tree in situations of splenomegaly and/or thrombocytopenia.

Important new understandings of the pathophysiology of GD reveal that Case deficiency affects more than only the macrophage load that causes them to become gaucher cells. They will pave the way for the creation of new forms of therapy.

It seems likely that medications that alter the neuronal phenotype will eventually be invented. More complexities molecular research will possibly eventually provide with crafted patient care. Recent therapeutic developments, such as the formation of novel enzymes and a new substrate inhibitor, are intriguing gains; however, research must continue. A regular assessment of GD patients is necessary to

identify obstacles in the disease's course, despite the fact they are asymptomatic.

Conflict of Interest: None of the authors have conflict of interest including finance.

REFERENCES

1. Ginzburg, L., Kacher, Y., & Futerman, A. H. (2004, August). The pathogenesis of glycosphingolipid storage disorders. In *Seminars in cell & developmental biology* (Vol. 15, No. 4, pp. 417-431). Academic Press.
2. Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008). Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). *Human mutation*, *29*(5), 567-583.
3. Sidransky, E. (2012). Gaucher disease: insights from a rare Mendelian disorder. *Discovery medicine*, *14*(77), 273-281.
4. Mehta, A. (2006). Epidemiology and natural history of Gaucher's disease. *European Journal of Internal Medicine*, *17*, S2-S5. Doi: 10.1016/j.ejim.2006.07.005. PMID: 17011471.
5. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., Rose, C., Billette de Villemeur, T., & Berger, M. G. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. *International journal of molecular sciences, 18*(2), 441. https://doi.org/10.3390/ijms18020441.
6. Mucci, J. M., Cuello, M. F., Kisinovsky, I., Larroude, M., Delpino, M. V., & Rozenfeld, P. A. (2015). Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology. *Blood Cells, Molecules, and Diseases*, *55*(2), 134-143.
7. Stirnemann, J., Belmatoug, N., Vincent, C., Fain, O., Fantin, B., & Mentré, F. (2010). Bone events and evolution of biologic markers in Gaucher disease before and during treatment. *Arthritis research & therapy*, *12*, 1-11.
8. Dekker, N., van Dussen, L., Hollak, C. E., Overkleeft, H., Scheij, S., Ghauharali, K., ... & Aerts, J. M. (2011). Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response. *Blood, The Journal of the American Society of Hematology*, *118*(16), e118-e127.
9. Robak, T., Urbanska-Rys, H., Jerzmanowski, P., Bartkowiak, J., Liberski, P., & Kordek, R. (2002). Lymphoplasmacytic Lymphoma with Monoclonal Gammopathy-related Pseudo-Gaucher Cell Infiltration in Bone Marrow and Spleen—Diagnostic and Therapeutic Dilemmas. *Leukemia & lymphoma*, *43*(12), 2343–2350.
10. Costello, R., O'Callaghan, T., & Sébahoun, G. (2006). Gaucher disease and multiple myeloma. *Leukemia & lymphoma*, *47*(7), 1365-1368.
11. Koprivica, V., Stone, D. L., Park, J. K., Callahan, M., Frisch, A., Cohen, I. J., ... & Sidransky, E. (2000). Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. *The American Journal of Human Genetics*, *66*(6), 1777-1786.
12. Yoshida, S., Kido, J., Matsumoto, S., Momosaki, K., Mitsubuchi, H., Shimazu, T., ... & Nakamura, K. (2016). Prenatal diagnosis of G aucher disease using next-generation sequencing. *Pediatrics International*, *58*(9), 946-949.
13. Dardis, A., Michelakakis, H., Rozenfeld, P., Fumic, K., Wagner, J., Pavan, E., Fuller, M., Revel-Vilk, S., Hughes, D., Cox, T., Aerts, J., & International Working Group of Gaucher Disease (IWGGD). (2022). Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. *Orphanet journal of rare diseases, 17*(1), 442. https://doi.org/10.1186/s13023-022-02573-6.
14. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., Rose, C., Billette de Villemeur, T., & Berger, M. G. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. *International journal of molecular sciences, 18*(2), 441. https://doi.org/10.3390/ijms18020441
15. Dahl, M., Doyle, A., Olsson, K., Månsson, J. E., Marques, A. R., Mirzaian, M., ... & Karlsson, S. (2015). Lentiviral gene therapy using cellular promoters cures type 1 Gaucher disease in mice. *Molecular Therapy*, *23*(5), 835-844.
16. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., Levade, T., Astudillo, L., Serratrice, J., Brassier, A., Rose, C., Billette de Villemeur, T., & Berger, M. G. (2017). A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. *International journal of molecular sciences, 18*(2), 441. https://doi.org/10.3390/ijms18020441
17. Stirnemann, J., Belmatoug, N., Camou, F., Serratrice, C., Froissart, R., Caillaud, C., ... & Berger, M. G. (2017). A review of Gaucher disease pathophysiology, clinical presentation and treatments. *International journal of molecular sciences*, *18*(2), 441. https://doi.org/10.3390/ijms18020441
18. Grabowski, G. A., Dinur, T., Gatt, S., & Desnick, R. J. Gaucher type (Ashkenazi) disease considerations for heterozygote detection and prenatal diagnosis. In: Desnick, R. J., Gatt, S. Grabowski, G.

A., eds. Gaucher disease: a century of delineation and research. Vol. 95 of Progress in clinical and biological.

19. Lee, R. E. (1982). The pathology of Gaucher disease In Desnick RJ, Gatt bowski GA, eds. Gaucher disease a century of delineation and research. Vol. 95 of Progress in clinical and biological research. New York: Alan R. Liss, 177-217.
20. O'Brien JS, Kishimoto Y. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J 1991; 5:301-8.
21. Beutler, E. (1979). Gaucher disease. In: Goodman RM, Motulsky AG, eds. Genetic diseases among Ashkenazi Jews. New York: Raven Press, 157-169.